oEvaluate response using iRANO criteria. oAgenus will isolate additional heat shock protein (HSP)-peptide complexes from “waste streams” generated during the manufacture of HSPPC-96 (Prophage) from GBM tumor tissue. From these HSP-peptide complexes, Agenus may generate a novel “multi-chaperone” vaccine that Agenus will evaluate in preclinical studies. 1.2 BACKGROUND AND RATIONALE 1.2.1 Disease Background Malignant gliomas, particularly GBM are nearly always fatal.